Welcome to our dedicated page for Novo-Nordisk A/S SEC filings (Ticker: NVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novo Nordisk’s dominance in diabetes and obesity care means its SEC disclosures hold critical clues about insulin pricing, GLP-1 adoption and the roll-out of obesity therapies. Whether you are decoding a 300-page Form 20-F (the foreign-issuer equivalent of a 10-K) or tracking executive stock sales ahead of clinical data, each filing is dense with data on global reimbursement, clinical milestones and manufacturing capacity.
Stock Titan’s AI reads every Novo Nordisk quarterly earnings report 10-Q filing, 6-K update and 8-K material event the moment they reach EDGAR, then delivers concise, plain-English explanations. Need real-time Novo Nordisk Form 4 insider transactions? Our alert system flags purchases and sales within minutes, while AI-powered summaries point out patterns. You will also find the full proxy statement executive compensation section—broken down so you can see how insulin sales targets shape bonus pools—plus notes on pending litigation, patent expiries and foreign currency impacts, all in one place.
Here’s how professionals use this page:
- Compare GLP-1 revenue trends quarter over quarter without combing through footnotes.
- Monitor Novo Nordisk insider trading Form 4 transactions before material announcements.
- Understand Novo Nordisk SEC documents with AI—no accounting degree required.
- Download Novo Nordisk annual report 10-K simplified (our annotated 20-F) for offline study.
- Receive instant context when a Novo Nordisk 8-K material events explained filing hits the wire.
From detailed earnings report filing analysis to executive stock transactions Form 4 tracking, we cover every document so you can make informed decisions faster.
Novo Nordisk is implementing a global transformation to speed decision-making and redirect resources toward diabetes and obesity growth opportunities. The company intends to reduce about 9,000 roles of its ~78,400 positions (approximately 5,000 of those in Denmark) and expects to deliver DKK 8 billion of annualised savings by the end of 2026. Management will incur one-off restructuring costs of DKK 8 billion, and it updated its full-year 2025 operating profit growth outlook to 4–10% at constant exchange rates, down from the prior 10–16% outlook—about a 6 percentage point reduction versus the August outlook. The transformation is presented as a response to recent slowdown in growth and increased organisational complexity, with additional initiatives planned to improve focus, performance culture and cost efficiency.
Novo Nordisk disclosed that Ludovic Helfgott, Executive Vice President, sold 12,000 Novo Nordisk B shares at DKK 326 per share on Nasdaq Copenhagen on 2025-08-08, for an aggregate amount of DKK 3,912,000. The company reported the transaction under Article 19 of Regulation No. 596/2014, with the sale recorded as an initial notification by the named executive.
The announcement also reiterates basic company information: Novo Nordisk markets its B shares on Nasdaq Copenhagen and ADRs on the New York Stock Exchange under the ticker NVO, employs about 78,400 people, and sells products in roughly 170 countries.
Form 6-K insider transaction report
On 8 Aug 2025, Novo Nordisk A/S (NVO) disclosed a managerial transaction under EU Market Abuse Regulation Article 19. Executive Vice President Ludovic Helfgott sold 28,710 class B shares (ISIN DK0062498333) on Nasdaq Copenhagen on 7 Aug 2025 at DKK 295.00 per share, generating gross proceeds of DKK 8,469,450.
The filing contains no financial results, strategic updates or additional insider dealings; it solely records this single transaction. Accordingly, investors receive limited insight into current operating performance, and the trade’s materiality is modest relative to Novo Nordisk’s market capitalisation.
Novo Nordisk (NVO) filed a Form 6-K disclosing insider transactions under EU Market Abuse Reg. 19. Executive Vice President Martin Holst Lange sold company B-shares on 7 Aug 2025 in two separate trades:
- 74 shares at DKK 316.75 (total DKK 23,439.50)
- 13,950 shares at DKK 316.48 (total DKK 4,414,898.43)
The combined sale amounts to 14,024 shares valued at DKK 4.44 million (≈ USD 0.65 million). One trade was executed through Citigroup Global Markets Europe AG; the larger block was carried out outside a trading venue. No purchases, option exercises, or other corporate events were reported, and no financial performance data accompanied the filing. The disclosure fulfills statutory reporting obligations but does not indicate any change in strategy, guidance, or fundamentals.
Event: On 4 Aug 2025 Novo Nordisk A/S (NYSE: NVO) filed a Form 6-K after receiving an unsolicited “mini-tender” from TRC Capital Investment Corp. to buy up to 2 million American Depositary Shares (ADSs), representing less than 0.045 % of the company’s total share capital. The offer applies only to ADSs, not ordinary shares.
Company stance: Novo Nordisk remains neutral, does not endorse the bid and advises holders to obtain current quotes, consult advisers, scrutinise the offer terms (including any price revisions) and act with caution. Management emphasises that mini-tenders target under 5 % of shares and therefore bypass full U.S. SEC tender-offer disclosure and procedural safeguards. Links to relevant SEC investor alerts and broker-dealer guidance are provided.
Investor impact: Because the offer covers an immaterial stake, no change in control, capital structure or operating fundamentals is expected. The filing’s primary purpose is to protect shareholders by flagging potential risks associated with mini-tender mechanics; it contains no financial results, guidance or strategic updates.
Novo Nordisk (NVO) files a Form 6-K announcing a leadership overhaul effective 7 Aug 2025. Executive vice president for International Operations Maziar “Mike” Doustdar is promoted to president & CEO, succeeding long-time leader Lars Fruergaard Jørgensen. Doustdar has overseen International Operations sales growth to about DKK 112 bn in 2024 and manages nearly 20,000 employees across 80 affiliates.
The Board also merges the Research & Early Development and Development divisions into one R&D unit. Martin Holst Lange, currently EVP Development, becomes chief scientific officer, while incumbent CSO Marcus Schindler will retire after a transition period. Emil Kongshøj Larsen moves into Executive Management as EVP International Operations, succeeding Doustdar.
The revised Executive Management team will comprise nine members, including CFO Karsten Munk Knudsen and US EVP David Moore. Investor and media conference calls are scheduled for 29 July 2025 at 14:30 CEST and 16:00 CEST, respectively.
FAQ
What is the current stock price of Novo-Nordisk A/S (NVO)?
What is the market cap of Novo-Nordisk A/S (NVO)?
